Fundraising FoxMetabolon, Inc.
Durham, US · Delaware corporation · 5 known investors
Find your way into Metabolon, Inc.
Each arrow is one introduction. Sign up to fill in the first one.
227 people can intro you to Rohan
Ask Alex Forrest-Hay to introduce you to Rohan F. Hastie
You →Alex · together at Metabolon, Inc. →Rohan
Sign up to find every way you can get introduced to Metabolon, Inc.
- Your email: who you already know at Metabolon, Inc., and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Metabolon, Inc. team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Metabolon provides metabolomics services and bioinformatics tools that measure small molecules to give biological context to research data. It serves biopharma, public health, consumer wellness, agriculture, and academic research clients across discovery, clinical, and translational studies.
Founders & leadership
GM
Gerald M. Haines IIExecutive
RF
Rohan F. HastiePresident and Chief Executive OfficerExecutive officer and director at Metabolon, a metabolomics services and bioinformatics company. Hastie has held leadership roles in sales, marketing, product development, and operations across multiple organizations and geographies.
Board
JO
John OxaalBoard director
RS
R. Scott BarryBoard director
RJ
R. John FletcherBoard director
BJ
B. Jefferson ClarkBoard director
CK
GF
Guy FishBoard director
CA
Carol A. MarinoBoard director
JL
Jan LundbergBoard director
RC
Robert CascellaBoard director
Investors · 5
Camden Partnerslisted by Camden PartnersOwings Mills
How we know: Camden Partners's portfolio page · Not right? Tell us
Essex Woodlands Healthcare Partnerslisted by Essex Woodlands Healthcare PartnersNew York · $20M – $80M
How we know: Essex Woodlands Healthcare Partners's portfolio page · funding news · press coverage · Not right? Tell us
Havencrest Capital Managementlisted by Havencrest Capital ManagementDallas
How we know: Havencrest Capital Management's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$89.4M disclosed across 7 rounds · 2015–2024
▶$7.5MraisedJan 2025 · 11 investors · Other Health CareRule 506(b)
▶$7.5MraisedJan 2025 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Gerald M. Haines IIExecutive Officer
- John OxaalDirector
- Jan LundbergDirector
- R. Scott BarryDirector
- Robert CascellaDirector
- R. John FletcherDirector
- Rohan F. HastieExecutive Officer, Director
- Todd SchermerhornDirector
- Offering amount
- $16.4M
- Amount sold
- $7.5M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedNov 2022 · 11 investors · Other Health CareRule 506(b)
▶$10MraisedNov 2022 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jan LundbergDirector
- Todd SchermerhornDirector
- Rohan F. HastieExecutive Officer, Director
- R. John FletcherDirector
- R. Scott BarryDirector
- Robert CascellaDirector
- John OxaalDirector
- John KurtzweilExecutive Officer
- Offering amount
- $41.6M
- Amount sold
- $10M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21.8MraisedSep 2020 · 11 investors · Other Health CareRule 506(b)
▶$21.8MraisedSep 2020 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John KurtzweilExecutive Officer
- R. Scott BarryDirector
- R. John FletcherDirector
- Todd SchermerhornDirector
- David PiersonDirector
- John OxaalDirector
- Robert CascellaDirector
- Rohan F. HastieExecutive Officer, Director
- Jan LundbergDirector
- Offering amount
- $48M
- Amount sold
- $21.8M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.8MraisedMar 2020 · 11 investors · Other Health CareRule 506(b)
▶$7.8MraisedMar 2020 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- R. Scott BarryDirector
- R. John FletcherDirector
- John OxaalDirector
- Rohan HastieExecutive Officer, Director
- John KurtzweilExecutive Officer
- Jan LundbergDirector
- David PiersonDirector
- Todd SchermerhornDirector
- Offering amount
- $9M
- Amount sold
- $7.8M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.3MraisedAug 2018 · 9 investors · Other Health CareRule 506(b)
▶$7.3MraisedAug 2018 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stephen FurlongExecutive Officer
- Santo J. CostaDirector
- John A. RyalsDirector
- Rohan HastieExecutive Officer, Director
- B. Jefferson ClarkDirector
- Rudy HowardDirector
- John OxaalDirector
- C. Thomas CaskeyDirector
- Scott BarryDirector
- David PiersonDirector
- John FletcherDirector
- Offering amount
- $8.3M
- Amount sold
- $7.3M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedDec 2016 · 2 investors · Other Health CareRule 506(b)
▶$30MraisedDec 2016 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John OxaalDirector
- John A. RyalsExecutive Officer, Director
- Scott BarryDirector
- C. Thomas CaskeyDirector
- Rudy HowardDirector
- B. Jefferson ClarkDirector
- David PiersonDirector
- Santo J. CostaDirector
- John FletcherDirector
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedMar 2015 · 4 investors · Other Health CareRule 506(b)
▶$5MraisedMar 2015 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- B. Jefferson ClarkDirector
- Santo J. CostaDirector
- John A. RyalsExecutive Officer, Director
- John OxaalDirector
- Christopher KerseyDirector
- C. Thomas CaskeyDirector
- Rudy HowardDirector
- Guy FishDirector
- Carol A. MarinoDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Metabolon, Inc..
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $297.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $148.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Metabolon, Inc. do?
- Metabolon provides metabolomics services and bioinformatics tools that measure small molecules to give biological context to research data. It serves biopharma, public health, consumer wellness, agriculture, and academic research clients across discovery, clinical, and translational studies.
- Who founded Metabolon, Inc.?
- Metabolon, Inc. was founded by John A. Ryals.
- Who are Metabolon, Inc.'s investors?
- Metabolon, Inc.'s investors include Camden Partners, Essex Woodlands Healthcare Partners, Havencrest Capital Management, Revelation Partners, Syngenta Group Ventures.
- How much funding has Metabolon, Inc. raised?
- Metabolon, Inc. has disclosed $89.4M raised across 7 rounds.
- Where is Metabolon, Inc. headquartered?
- Metabolon, Inc. is headquartered in Durham, US.